The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Allogeneic T Cell Therapies Market Change Between 2026 And 2030?
The allogeneic t cell therapies market has experienced strong expansion in recent years. This market is projected to grow from $1.26 billion in 2025 to $1.38 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.4%. The historical increase can be attributed to several factors, including the limitations of autologous therapies, the initial success of CAR-T treatments, an increasing prevalence of cancer, ongoing advancements in immunotherapy research, and the broader expansion of hospital-based oncology.
The allogeneic t cell therapies market is anticipated to experience robust expansion over the next few years, with its size projected to reach $1.98 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.4%. This growth during the forecast period is primarily attributed to factors such as the demand for cost-effective cell therapies, the expansion of oncology pipelines, improvements in donor matching, supportive regulatory frameworks for cell therapies, and the increasing number of specialty cancer centers. Significant trends influencing the market include a shift towards off-the-shelf cell therapies, a rise in oncology-related clinical trials, an escalating focus on scalable cell manufacturing, enhanced investment in cell engineering, and the proliferation of specialized treatment centers.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18952&type=smp
What Key Growth Drivers Are Influencing The Allogeneic T Cell Therapies Market?
The allogeneic T cell therapies market is anticipated to expand due to the rising incidence of cancer. Cancer is defined as a collection of illnesses marked by the unregulated proliferation and dissemination of atypical cells within the body. Several elements contribute to the increasing number of cancer diagnoses, including extended lifespans, evolving lifestyles, environmental risk factors, infections, genetic predispositions, and shifts in reproductive behaviors, all of which together lead to a greater occurrence and identification of the condition. Allogeneic T cell therapies involve administering genetically modified donor T cells, which identify specific tumor antigens, into cancer patients to target and eradicate malignant cells. An illustration of this trend is data from May 2024 by the National Cancer Institute, a US-based government agency, indicating approximately 18.1 million cancer survivors in the United States. This number is projected to increase to 22.5 million by 2032. Furthermore, projections for 2040 suggest that annual new cancer cases will total 29.9 million, and cancer-related fatalities are estimated to climb to 15.3 million. Consequently, the growing prevalence of cancer acts as a significant impetus for the allogeneic T cell therapies market.
What Key Segment Areas Are Included In The Allogeneic T Cell Therapies Market Assessment?
The allogeneic t cell therapies market covered in this report is segmented –
1) By Product Type: Chimeric Antigen Receptor (CAR) T Cell Therapies, T Cell Receptor (TCR) Therapies
2) By Antigen Type: CD 19, CD 20, Egfrvlll, GD2, CD22, CD30, CD33, Meso, HER1, Other Antigen Types
3) By Therapeutics Indications: Cancer, Autoimmune Diseases, Infectious Diseases, Other Therapeutics Indications
4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Chimeric Antigen Receptor (CAR) T Cell Therapies: CD19-targeted CAR T Therapies, BCMA-targeted CAR T Therapies, CD22-targeted CAR T Therapies
2) By T Cell Receptor (TCR) Therapies: Neoantigen-targeted TCR Therapies, Viral Antigen-targeted TCR Therapies
Which Trends Are Influencing The Expansion Of The Allogeneic T Cell Therapies Market?
Major companies operating in the allogeneic T cell therapies market are concentrating on developing advanced products, such as gene-edited donor-derived CAR-T and TCR T cell therapies, to secure a competitive advantage in the market. Gene-edited donor-derived T cell therapies refer to immune-effector T cells obtained from healthy donors that are genetically manipulated (e.g., with knocked-out T cell receptor (TCR) and HLA genes, inserted CAR/TCR constructs, and built-in safety switches) to create universal off-the-shelf products that can be mass-produced, cryopreserved, and rapidly administered without requiring patient-specific manufacture. For instance, in January 2024, Allogene Therapeutics, a US-based cell therapy company, announced its 2024 platform vision, which focuses on ALPHA3. This program represents the industry’s first pivotal trial of an allogeneic CAR-T programme utilizing gene-editing technologies to eliminate graft-versus-host disease (GvHD) risk and facilitate rapid donor-based delivery. The product features include donor-derived T cells edited to remove endogenous TCR and HLA molecules to minimize host immune rejection and GvHD, a chimeric antigen receptor targeting a tumour antigen enabling swift anti-cancer activity, and a cryopreserved ready-to-infuse format to shorten time to treatment compared to autologous therapies.
Which Companies Are Influencing The Allogeneic T Cell Therapies Market?
Major companies operating in the allogeneic t cell therapies market are Allogene Therapeutics Inc., Cellectis SA, Fate Therapeutics Inc., Poseida Therapeutics Inc., Atara Biotherapeutics Inc., Autolus Therapeutics Plc, Adaptimmune Therapeutics Plc, Immatics NV, Medigene AG, Celyad Oncology SA, Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Sangamo Therapeutics Inc., MaxCyte Inc., Tessa Therapeutics Pte Ltd., Cell Medica Inc., Bellicum Pharmaceuticals Inc., Enlivex Therapeutics Ltd., Sorrento Therapeutics Inc.
Access The Complete Allogeneic T Cell Therapies Market Report:
https://www.thebusinessresearchcompany.com/report/allogeneic-t-cell-therapies-global-market-report
What Is The Largest Regional Market In The Allogeneic T Cell Therapies Market?
North America was the largest region in the allogeneic T cell therapies market in 2025. The regions covered in the allogeneic t cell therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Allogeneic T Cell Therapies Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=18952&type=smp
Browse Through More Reports Similar to the Global Allogeneic T Cell Therapies Market 2026, By The Business Research Company
Allogeneic Cell Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/allogeneic-cell-therapy-global-market-report
Cells Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report
Cell Therapy Technologies Market Report 2026
https://www.thebusinessresearchcompany.com/report/cell-therapy-technologies-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model